Date: 2014-06-10
Type of information: Series C financing round
Company: to-BBB (The Netherlands)
Investors: new and existing investors
Amount: €10 million
Funding type: series C financing round
Planned used: to-BBB, a biotechnology will use the funds to strengthen its developmental efforts while expanding its clinical programs. The Company combines existing drugs with to-BBB’s proprietary G-Technology® to enhance drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases. The second product 2B3-201 for MS relapses and other neuroinflammatory diseases entered a Phase I clinical study in December 2013. .
Others: * On June 30, 2014, to-BBB, a biotechnology company developing novel treatments for devastating brain diseases, announced the successful finalization of a round C financing of €10 million with new and existing investors. The company also announced the appointment of Dr. Pericles (Perry) Calias as Senior Vice President Translational Medicine and the appointment of Leonard Kruimer as interim CEO to replace Willem van Weperen, who accepted a career opportunity outside the company.
Dr. Pericles Calias has recently joined to-BBB as Senior Vice President Translational Medicine. As such, he will be responsible for expanding and accelerating the development of the pre-clinical portfolio. Dr. Calias will coordinate the early regulatory, non-clinical, manufacturing and quality efforts as to-BBB continues its clinical development programs. Prior to joining to-BBB, Pericles Calias led the development of the CNS protein replacement programs at Shire.
Therapeutic area: CNS diseases - Neurodegenerative diseases - Cancer - Oncology - Neuroinflammatory diseases
